The American Journal of Medicine
Volume 119, Issue 5, Supplement 1 , Pages S31-S39 , May 2006

Heart and Kidney: Fatal Twins?

  • Eberhard Ritz, MD

      Affiliations

    • Corresponding Author InformationRequest for reprints should be addressed to Eberhard Ritz, MD, Department of Nephrology, Ruprecht-Karl University, Im Neuenheimer Feld 162, D-69162 Heidelberg, Germany.

References 

  1. Sarnak MJ , Levey AS , Schoolwerth AC , et al.   Kidney disease as a risk factor for development of cardiovascular disease (a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention) . Circulation . 2003;108:2154–2169
  2. Hillege HL , Janssen WM , Bak AA , et al.   Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity . J Intern Med . 2001;249:519–526
  3. Gerstein HC , Mann JF , Yi Q , et al.   Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals . JAMA . 2001;286:421–426
  4. Romundstad S , Holmen J , Kvenild K , et al.   Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trondelag Health Study (HUNT), Norway . Am J Kidney Dis . 2003;42:466–473
  5. Verhave JC , Hillege HL , Burgerhof JG , et al.   Cardiovascular risk factors are differently associated with urinary albumin excretion in men and women . J Am Soc Nephrol . 2003;14:1330–1335
  6. Mykkanen L , Zaccaro DJ , Wagenknecht LE , et al.   Microalbuminuria is associated with insulin resistance in nondiabetic subjects (the insulin resistance atherosclerosis study) . Diabetes . 1998;47:793–800
  7. Saad MF , Anderson RL , Laws A , et al.   A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance (Insulin Resistance Atherosclerosis Study) . Diabetes . 1994;43:1114–1121
  8. Brantsma AH , Bakker SJL , Hillege HL , et al.   Urinary albumin excretion is an independent predictor of development of type 2 diabetes mellitus . [abstract] J Am Soc Nephrol . 2005;15:566a
  9. Gross ML , Hanke W , Koch A , et al.   Intraperitoneal protein injection in the axolotl (the amphibian kidney as a novel model to study tubulointerstitial activation) . Kidney Int . 2002;62:51–59
  10. Scuteri A , Najjar SS , Morrell CH , Lakatta EG . The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study . Diabetes Care . 2005;28:882–887
  11. National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report . Circulation . 2002;106:3143–3421
  12. Chen J , Muntner P , Hamm LL , et al.   The metabolic syndrome and chronic kidney disease in U.S. adults . Ann Intern Med . 2004;140:167–174
  13. Stern MP , Williams K , Gonzalez-Villalpando C , et al.   Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? . Diabetes Care . 2004;27:2676–2681
  14. Engeli S , Bohnke J , Gorzelniak K , et al.   Weight loss and the renin-angiotensin-aldosterone system . Hypertension . 2005;45:356–362
  15. Shinozaki K , Ayajiki K , Nishio Y , et al.   Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance . Hypertension . 2004;43:255–262
  16. Guzik TJ , Mussa S , Gastaldi D , et al.   Mechanisms of increased vascular superoxide production in human diabetes mellitus (role of NAD(P)H oxidase and endothelial nitric oxide synthase) . Circulation . 2002;105:1656–1662
  17. Wagner J , Gehlen F , Ciechanowicz A , Ritz E . Angiotensin II receptor type 1 gene expression in human glomerulonephritis and diabetes mellitus . J Am Soc Nephrol . 1999;10:545–551
  18. Christlieb AR , Kaldany A , D’Elia JA . Plasma renin activity and hypertension in diabetes mellitus . Diabetes . 1976;25:969–974
  19. Price DA , Porter LE , Gordon M , et al.   The paradox of the low-renin state in diabetic nephropathy . J Am Soc Nephrol . 1999;10:2382–2391
  20. Brenner BM , Cooper ME , de Zeeuw D , et al.   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy . N Engl J Med . 2001;345:861–869
  21. Lewis EJ , Hunsicker LG , Clarke WR , et al.   Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes . N Engl J Med . 2001;345:851–860
  22. Viberti G , Wheeldon NM . Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus (a blood pressure-independent effect) . Circulation . 2002;106:672–678
  23. Kidney Disease Outcomes Quality Initiative (K/DOQI) . K-DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease . Am J Kidney Dis . 2004;43(suppl 1):S1–S290
  24. Adamczak M , Gross ML , Krtil J , et al.   Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats . J Am Soc Nephrol . 2003;14:2833–2842
  25. Parving HH , Lehnert H , Bröchner-Mortensen J , et al.   The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes . N Engl J Med . 2001;345:870–878
  26. Aranda P , Aranda FJ , Frutos MA , Lopez de Novales E , Arandas Granados PJ , Ruilope LM . Comparative long-term renoprotective effects of usual versus high dose of telmisartan in nondiabetic nephropathies . J Hypertens . 2004;22(suppl 2):S81–S82
  27. Andersen S , Brochner-Mortensen J , Parving HH . Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria . Diabetes Care . 2003;26:3296–3302
  28. Lindholm LH , Ibsen H , Dahlöf B , et al.   Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) (a randomised trial against atenolol) . Lancet . 2002;359:1004–1010
  29. Ruggenenti P , Fassi A , Ilieva AP , et al.   Preventing microalbuminuria in type 2 diabetes . N Engl J Med . 2004;351:1944–1951
  30. Chobanian AV , Bakris GL , Black HR , et al.   The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure . JAMA . 2003;289:2560–2572
  31. Wang TJ , Evans JC , Meigs JB , et al.   Low-grade albuminuria and the risks of hypertension and blood pressure progression . Circulation . 2005;111:1370–1376
  32. Klausen K , Borch-Johnsen K , Feldt-Rasmussen B , et al.   Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes . Circulation . 2004;110:32–35
  33. Ibsen H , Wachtell K , Olsen MH , et al.   Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy . J Hypertens . 2004;22:1805–1811
  34. Hillege HL , Fidler V , Diercks GF , et al.   Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population . Circulation . 2002;106:1777–1782
  35. Asselbergs FW , Diercks GF , Hillege HL , et al.   Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria . Circulation . 2004;110:2809–2816
  36. Ibsen H , Olsen MH , Wachtell K , et al.   Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients (Losartan Intervention for Endpoint Reduction in Hypertension Study) . Hypertension . 2005;45:198–202
  37. Wachtell K , Ibsen H , Olsen MH , et al.   Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy (the LIFE study) . Ann Intern Med . 2003;139:901–906
  38. Rachmani R , Levi Z , Lidar M , et al.   Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus (lessons from an 8-year follow-up study of 599 patients) . Diabetes Res Clin Pract . 2000;49:187–194
  39. Jager A , van Hinsbergh VW , Kostense PJ , et al.   C-reactive protein and soluble vascular cell adhesion molecule-1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk . Arterioscler Thromb Vasc Biol . 2002;22:593–598
  40. Nagai Y , Yao L , Kobori H , et al.   Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats . J Am Soc Nephrol . 2005;16:703–711
  41. Shulman NB , Ford CE , Hall WD , et al.  Hypertension Detection and Follow-up Program Cooperative Group   Prognostic value of serum creatinine and effect of treatment of hypertension on renal function (results from the hypertension detection and follow-up program) . Hypertension . 1989;13(5 suppl):I80–I93
  42. Levey AS , Coresh J , Balk E , et al.   National Kidney Foundation practice guidelines for chronic kidney disease (evaluation, classification, and stratification) . Ann Intern Med . 2003;139:137–147
  43. National Kidney Foundation . K/DOQI clinical practice guidelines for chronic kidney disease (evaluation, classification, and stratification) . Am J Kidney Dis . 2002;39(suppl 1):S1–S266
  44. Cockcroft DW , Gault MH . Prediction of creatinine clearance from serum creatinine . Nephron . 1976;16:31–41
  45. Levey AS , Bosch JP , Lewis JB , et al.  Modification of Diet in Renal Disease Study Group   A more accurate method to estimate glomerular filtration rate from serum creatinine (a new prediction equation) . Ann Intern Med . 1999;130:461–470
  46. Shlipak MG , Sarnak MJ , Katz R , et al.   Cystatin C and the risk of death and cardiovascular events among elderly persons . N Engl J Med . 2005;352:2049–2060
  47. Henry RM , Kostense PJ , Bos G , et al.   Mild renal insufficiency is associated with increased cardiovascular mortality (the Hoorn Study) . Kidney Int . 2002;62:1402–1407
  48. Mann JF , Gerstein HC , Pogue J , et al.   Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril (the HOPE randomized trial) . Ann Intern Med . 2001;134:629–636
  49. Go AS , Chertow GM , Fan D , et al.   Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization . N Engl J Med . 2004;351:1296–1305
  50. Wright RS , Reeder GS , Herzog CA , et al.   Acute myocardial infarction and renal dysfunction (a high-risk combination) . Ann Intern Med . 2002;137:563–570
  51. Anavekar NS , McMurray JJ , Velazquez EJ , et al.   Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction . N Engl J Med . 2004;351:1285–1295
  52. Sever PS , Dahlof B , Poulter NR , et al.   Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA) (a multicentre randomised controlled trial) . Lancet . 2003;361:1149–1158
  53. Shlipak MG , Fried LF , Crump C , et al.   Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency . Circulation . 2003;107:87–92
  54. Becker B , Kronenberg F , Kielstein JT , et al.   Renal insulin resistance syndrome, adiponectin, and cardiovascular events in patients with kidney disease (the Mild and Moderate Kidney Disease Study) . J Am Soc Nephrol . 2005;16:1091–1098
  55. Benson SC , Pershadsingh HA , Ho CI , et al.   Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARg-modulating activity . Hypertension . 2004;43:993–1002
  56. Buzello M , Tornig J , Faulhaber J , et al.   The apolipoprotein E knockout mouse (a model documenting accelerated atherogenesis in uremia) . J Am Soc Nephrol . 2003;14:311–316
  57. Bursztyn M , Motro M , Grossman E , Shemesh J . Accelerated coronary artery calcification in mildly reduced renal function of high-risk hypertensives (a 3-year prospective observation) . J Hypertens . 2003;21:1953–1959
  58. Modlinger PS , Wilcox CS , Aslam S . Nitric oxide, oxidative stress, and progression of chronic renal failure . Semin Nephrol . 2004;24:354–365
  59. Lansang MC , Hollenberg NK . Renal perfusion and the renal hemodynamic response to blocking the renin system in diabetes (are the forces leading to vasodilation and vasoconstriction linked?) . Diabetes . 2002;51:2025–2028
  60. Kielstein JT , Boger RH , Bode-Boger SM , et al.   Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease . J Am Soc Nephrol . 2002;13:170–176
  61. de Zeeuw D , El Nahas AM . Albuminuria, a new target for therapy (treat the kidney to protect the heart) . In:  El Nahas AM editors. Kidney Diseases in the Developing World and Ethnic Minorities . New York: Marcel Dekker; 2005;

PII: S0002-9343(06)00103-3

doi: 10.1016/j.amjmed.2006.01.012

The American Journal of Medicine
Volume 119, Issue 5, Supplement 1 , Pages S31-S39 , May 2006

Article Tools

* Image Usage & Resolution